SCHEMBL20134769

SCHEMBL20134769

Cc1cc(C2CC2)cnc1N1CCN(C(=O)c2ccc(C3(C(C)C)NC(=O)NC3=O)cc2)CC1

nearest known ligand 0.36

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.36
ALDH1A1 P00352 2/20 0.35
EGLN1 Q9GZT9 1/20 0.35
ADAMTS5 Q9UNA0 8/20 0.34
ADAM17 P78536 7/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPK1 P28482 1/20 0.34
FASN P49327 3/20 0.34
CRBN Q96SW2 1/20 0.33
MMP2 P08253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688547 0.90 ADAMTS5 (0.35) SLC6A7ALDH1A1ADAMTS5ADAM17FASN
SCHEMBL20135538 0.90 ADAMTS5 (0.35) SLC6A7ALDH1A1ADAMTS5ADAM17FASN
SCHEMBL20134972 0.89 ALDH1A1 (0.40) SLC6A7ALDH1A1ADAMTS5ADAM17KDM4E
SCHEMBL20134989 0.89 ALDH1A1 (0.40) SLC6A7ALDH1A1ADAMTS5ADAM17KDM4E
SCHEMBL20135670 0.88 HTT (0.37) ADAMTS5ADAM17KDM4EMMP2
SCHEMBL29689083 0.88 HTT (0.37) ADAMTS5ADAM17KDM4EMMP2
SCHEMBL20134934 0.88 SLC6A7 (0.38) SLC6A7ALDH1A1EGLN1ADAMTS5ADAM17
SCHEMBL20134930 0.88 SLC6A7 (0.38) SLC6A7ALDH1A1EGLN1ADAMTS5ADAM17
SCHEMBL20135085 0.86 LMNA (0.41) ALDH1A1ADAMTS5ADAM17KDM4EFASN
SCHEMBL29688861 0.86 LMNA (0.41) ALDH1A1ADAMTS5ADAM17KDM4EFASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN claimed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US claimed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US claimed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP claimed
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 SLC6A7 3698/4885ALDH1A1 584/4885EGLN1 412/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 SLC6A7 3473/4885ALDH1A1 610/4885EGLN1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.